Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M905Revenue $M81.4Net Margin (%)-151.4Z-Score-3.2
Enterprise Value $M785EPS $-0.1Operating Margin %-283.1F-Score3
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-151.4Higher ROA y-yN
Price/Book11.810-y EBITDA Growth Rate %-26.4Quick Ratio3.5Cash flow > EarningsY
Price/Sales26.35-y EBITDA Growth Rate %-57.2Current Ratio3.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-15.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-51.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M220ROI % (ttm)-11.9Gross Margin Increase y-yN

Gurus Latest Trades with ARNA

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARNAKen Fisher 2013-12-31 Buy $4.08 - $6.66
($5.22)
$ 4.28-18%New holding, 11000 sh.11,000
ARNAMario Gabelli 2011-03-31 Sold Out $1.41 - $2.16
($1.7)
$ 4.28152%Sold Out0
ARNAMario Gabelli 2010-12-31 Buy $1.27 - $2.38
($1.58)
$ 4.28171%New holding, 13000 sh.13,000
ARNAGeorge Soros 2008-06-30 Sold Out -0.01%$4.67 - $6.92
($5.5)
$ 4.28-22%Sold Out0
ARNAGeorge Soros 2006-12-31 Sold Out -0.05%$12.95 - $17.39
($14.6)
$ 4.28-71%Sold Out0
ARNAGeorge Soros 2006-09-30 Add0.04%$9.23 - $12.22
($10.9)
$ 4.28-61%Add 266%55,000
ARNAGeorge Soros 2006-06-30 Buy 0.02%$10.54 - $15.58
($13.3)
$ 4.28-68%New holding, 15000 sh.15,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARNA is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ARNA Ken Fisher 2014-12-3111,00000
Premium Most recent portfolio changes are included for Premium Members only!


ARNA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SPECTOR STEVEN WEVP, General Counsel & Sec 2015-01-08Sell45,000$6.26-27.96view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2015-01-07Sell50,000$5.49-17.85view
LIEF JACKChairman, President and CEO 2014-07-01Sell223,525$5.85-22.91view
BELCHER DONALD DDirector 2014-06-27Sell2,473$5.85-22.91view
SPECTOR STEVEN WEVP, General Counsel & Sec 2014-05-12Sell45,000$7.05-36.03view
BELCHER DONALD DDirector 2014-05-06Sell4,176$7-35.57view
HIXSON HARRY F JRDirector 2014-04-22Sell36,900$6.31-28.53view
Nova Tina SusanDirector 2014-04-14Sell35,000$6.22-27.49view
BELCHER DONALD DDirector 2014-04-01Sell1,905$6.45-30.08view
SHANAHAN WILLIAM R JRSVP & Chief Medical Officer 2014-04-01Sell60,000$6.37-29.2view

Press Releases about ARNA :

    Quarterly/Annual Reports about ARNA:

    News about ARNA:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial Results Nov 16 2013 
    WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW Apr 07 2013 
    comment on ARNA Mar 15 2013 
    comment on ARNA Mar 02 2013 
    WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC Oct 07 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 


    More From Other Websites
    Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Feb 27 2015
    Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference Feb 23 2015
    Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call... Feb 23 2015
    Sporting Goods Stores Arena and New Balance to Open in SEC RayON Feb 23 2015
    Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus Feb 20 2015
    Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference Feb 18 2015
    Announcement regarding the Acquisition of the Naming Rights for the Tomakomai City Hakucho Arena Feb 13 2015
    Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for... Feb 03 2015
    Arena Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference Feb 02 2015
    Arena Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference Feb 02 2015
    ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 23 2015
    Coverage initiated on Arena Pharm by RBC Capital Mkts Jan 23 2015
    Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics Jan 23 2015
    Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
    Stock Pops & Drops: CHL, ARNA, MBLY & ANTM Jan 21 2015
    Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity... Jan 21 2015
    Arena Pharmaceuticals Announces Agreement to Sell Common Stock Jan 21 2015
    Arena Pharmaceuticals Announces Agreement to Sell Common Stock Jan 21 2015
    Arena Pharmaceuticals Announces Agreement to Sell Common Stock Jan 21 2015
    ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jan 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK